A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults

NCT04668339 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

581

Enrollment

INDUSTRY

Sponsor class

Stopped A decision was made to terminate the study for operational/business reasons. The study was not terminated for reasons of safety or immunogenicity.

Conditions

Covid19
SARS-CoV Infection
Corona Virus Infection

Interventions

BIOLOGICAL: ARCT-021 single dose priming
BIOLOGICAL: ARCT-021 two lower dose priming
BIOLOGICAL: ARCT-021 two higher dose priming
BIOLOGICAL: Placebo (two doses), priming
BIOLOGICAL: Randomized booster
BIOLOGICAL: Placebo booster

Sponsor

Arcturus Therapeutics, Inc.